Therapeutic Effects of Survivin Antisense Oligonucleotide on Nude Mice Bearing Human Pancreatic Carcinoma Xenograft

LIU Jiang-wei,LI Kai-zong,DOU Ke-feng,ZHANG Dong-hui,XU Yong-hua,ZHANG Dong,FENG De-yuan,YANG Zi-gen
DOI: https://doi.org/10.13241/j.cnki.pmb.2008.11.048
2008-01-01
Abstract:Objective:To investigate the therapeutic effects of COX-2 inhibitor celecoxib in combination with survivin antisense oligonucleotide (ASODN)on nude mice bearing human pancreatic cancer xenograft.Methods:The nude mouse model of pancreatic cancer was established with human pancreatic cancer cell line BxPC-3.The mice bearing tumor were randomly divided into 4 groups: control group,celecoxib group (provided with water containing 1000ppm celecoxib),survivin ASODN group (intratumorally injected with survivin ASODN at the concentration of 40μg/200μL per mouse each time),combination group (provided with water containing 1000 ppm celecoxib and at the same time intratumorally injected with survivin ASODN at the concentration of 40μg/200μL per mouse each time).The tumor size and volume were measured at different time,the nude mice were sacrificed 35 days after the inoculated began. The weight of each tumor was weighed,the caspase-3 activity was evaluated using a caspase-3 assay kit;the expression of proliferating cell nuclear antigen(PCNA)and microvessel density(MVD)were observed using immunohistochemistry.Results:The tumor volumes in the three experimental groups were significantly smaller than that in the control group (491.97±4.62mm3,427.34±14.62mm~3,300.39±6.59 mm~3 vs 703.56±12.51 mm~3,P0.01),the tumor volume of the combinition group was significantly smaller than that of the celecoxib group or the survivin ASODN alone.The tumor inhibition rate of the three experimental groups were 32.26%, 50.86%,62.07%,respectively.The caspase-3 activities were significantly higher in the three experimental groups than that in in the con- trol group (0.026±0.003,0.040±0.018,0.059±0.005 vs 0.006±0.001,P0.01).The caspase-3 activities of the combinition group were significantly higher than that in the celecoxib group(P0.01)or the survivin ASODN alone(P0.05).The expressions of PCNA and MVD were significantly lower in the three experimental groups than that in the control group (P0.01,or P0.05),and the expressions of PCNA and MVD were significantly lower in the combinition group than that in the celecoxib group or the survivin ASODN alone (P0. 01,or P0.05).Conclusion:The COX-2 inhibitor celecoxib in combination with survivin antisense oligonucleotide (ASODN)on nude mice bearing human pancreatic cancer may signifcantly inhibit the growth of human pancreatic cancer in nude mouse model through acti- vating the caspase-3 activity to induce apoptosis and suppressing the proliferation and angiogenesis of the pancreatic cancer cells.The combiniation target of COX-2 and survivin may provide a new way for the treatment of pancreatic cancer.
What problem does this paper attempt to address?